Advanced Solid TumorsPhase 1NCT05114759
A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
A Phase 1 study testing SHR-A2009 in people with Advanced Solid Tumors, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd. at 16 sites in 3 countries.
Trial summary
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-A2009 for injection in patients with advanced solid tumors. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Advanced Solid Tumors
- What is being tested?
- SHR-A2009
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 176 participants
- Where
- 16 sitesin 3 countries
- Study dates
- 4 Jan 2022to 30 Dec 2026
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors which is relapsed or refractory to standard treatment, or lack of standard treatment, or standard treatment is not applicable currently;
- Have at least one measurable tumor lesion per RECIST v1.1 (patients with only non-target lesions are allowed to be enrolled in dose escalation stage);
- ECOG performance status of 0-1;
- Life expectancy ≥ 12 weeks;
- Adequate bone marrow and organ function .
- Subjects must voluntarily agree to participate in the trial and sign a written informed consent form.
Who cannot join
- Patients with symptomatic central nervous system metastases or meningeal metastases;
- Ongoing or previous anti-tumor therapies within 4 weeks prior to the first dose of study drug;
- Prior treatment with antibody-drug conjugate (ADC) consisting of topoisomerase I inhibitors;
- History of serious cardiovascular and cerebrovascular diseases;
- Severe infection within 4 weeks prior to the first dose;
- Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per NCI-CTCAE v5.0.
Trial locations and contacts
16 sites in 3 countries.
16 sites in 3 countries
China11 sites
The First Hospital of JiLin University
Changchun, Jlin, 132000
Hunan Cancer Hospital
Changsha, Hunan, 410000
Sichuan Cancer Hospital & Institute
Chengdu, Sichuan, 610000
West China Hospital,Sichuan University
Chengdu, Sichuan, 610000
Chongqing Cancer Hospital
Chongqicun, Chongqi, 400000
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, 350000
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080
Shandong Cancer Hospital&Institute
Jinan, Shandong, 250000
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 650000
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330000
The Second Affiliated Hospital of Air Force Military University Tangdu Hospital
Xi’an, Shanxi, 710000
South Korea3 sites
Seoul National University Hospital
Seoul, Seoul, 03080
Asan Medical Center
Seoul, Seoul, 05505
Samsung Medical Center
Seoul, Seoul, 06351
Japan2 sites
National Cancer Center Hospital East
Chiba, Chiba, 277-8577
National Cancer Center Hospital
Tokyo, Tokyo, 104-0045
About this study
Official title: A Phase I, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-A2009 for injection in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors
- Being tested
- SHR-A2009
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SHR-A2009Drug
In dose Escalation:
SHR-A2009 will be administered intravenously. Six dose levels are preset.
In dose Expansion:
2 to 3 dose cohorts will be selected for dose expansion stage.
In indication Expansion:
Indications will be selected to evaluate preliminary efficacy.
| Study group | Role | What they receive |
|---|---|---|
| SHR-A2009 for Injection will be administrated per dose level in which the patients are assigned. | Experimental | Not described Receives: Drug: SHR-A2009 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maximum tolerated dose (MTD) or maximum administered dose (MAD).
Incidence and category of dose limiting toxicities (DLTs) during the first 21-day cycle of SHR-A2009 treatment.
Measured: From Day 1 to Day 21
Recommended Phase 2 dose (RP2D)
RP2D will be determined on the basis of evaluation on MTD/MAD, PK, efficacy data in dose escalation and dose expansion stages.
Measured: From Day 1 to 90 days after last dose
Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) ([CTCAE] v5.0)
Assess safety and tolerability of SHR-A2009 by way of adverse events (CTCAE v5.0).
Measured: From Day 1 to 90 days after last dose
Secondary outcomes (9)
Tmax of SHR-A2009
Time to maximum concentration of SHR-A2009
Measured: approximately 6 months
Cmax of SHR-A2009
Maximum concentration of SHR-A2009
Measured: approximately 6 months
AUC0-t of SHR-A2009
area under the concentration-time curve from time 0 to the last measurable concentration time point of SHR-A2009
Measured: approximately 6 months
AUC0-∞ of SHR-A2009
area under the concentration-time curve from time 0 to infinity of SHR-A2009
Measured: approximately 6 months
Immunogenicity of SHR-A2009
Anti-SHR-A2009 antibody (ADA)
Measured: approximately 9 months
Overall response rate (ORR)
Evaluated using RECIST 1.1
Measured: approximately within 36 months
Duration of response (DoR)
Evaluated using RECIST 1.1
Measured: approximately within 36 months
Disease control rate (DCR)
Evaluated using RECIST 1.1
Measured: approximately within 36 months
Progression-free survival (PFS)
Evaluated using RECIST 1.1
Measured: approximately within 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Nov 2021
- Study start4 Jan 2022
- Primary completion30 Dec 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Solid TumorsStudies of the same condition, open and under way.
- More trials run by Suzhou Suncadia Biopharmaceuticals Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single arm study of SHR-A2009
- Masking
- None (open label)
- Enrolment
- 176 participants (actual)
Sponsor and investigators
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05114759
- Sponsor's protocol ID
- SHR-A2009-I-101
- Status last verified
- Jul 2026
- First submitted
- 20 Oct 2021
- Last updated
- 16 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
- ClinicalTrials.gov ID
- NCT05114759
- Acronym / sponsor ID
- SHR-A2009-I-101
- Conditions
- Advanced Solid Tumors
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 176 participants (actual)
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 4 Jan 2022 (actual)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 10 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-A2009 for injection in patients with advanced solid tumors.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single arm study of SHR-A2009
| Arm | Type | Receives |
|---|---|---|
| SHR-A2009 for Injection will be administrated per dose level in which the patients are assigned. | Experimental | Drug: SHR-A2009 |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors which is relapsed or refractory to standard treatment, or lack of standard treatment, or standard treatment is not applicable currently;
- Have at least one measurable tumor lesion per RECIST v1.1 (patients with only non-target lesions are allowed to be enrolled in dose escalation stage);
- ECOG performance status of 0-1;
- Life expectancy ≥ 12 weeks;
- Adequate bone marrow and organ function .
Key exclusion criteria (6 listed)
- Patients with symptomatic central nervous system metastases or meningeal metastases;
- Ongoing or previous anti-tumor therapies within 4 weeks prior to the first dose of study drug;
- Prior treatment with antibody-drug conjugate (ADC) consisting of topoisomerase I inhibitors;
- History of serious cardiovascular and cerebrovascular diseases;
- Severe infection within 4 weeks prior to the first dose;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SHR-A2009In dose Escalation: SHR-A2009 will be administered intravenously. Six dose levels are preset. In dose Expansion: 2 to 3 dose cohorts will be selected for dose expansion stage. In indication Expansion: Indications will be selected to evaluate preliminary efficacy. | Drug | SHR-A2009 for Injection will be administrated per dose level in which the patients are assigned. |
Primary outcome
Maximum tolerated dose (MTD) or maximum administered dose (MAD).
Time frame: From Day 1 to Day 21
Incidence and category of dose limiting toxicities (DLTs) during the first 21-day cycle of SHR-A2009 treatment.
Recommended Phase 2 dose (RP2D)
Time frame: From Day 1 to 90 days after last dose
RP2D will be determined on the basis of evaluation on MTD/MAD, PK, efficacy data in dose escalation and dose expansion stages.
Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) ([CTCAE] v5.0)
Time frame: From Day 1 to 90 days after last dose
Assess safety and tolerability of SHR-A2009 by way of adverse events (CTCAE v5.0).
9 secondary outcomes
Tmax of SHR-A2009
Time frame: approximately 6 months
Cmax of SHR-A2009
Time frame: approximately 6 months
AUC0-t of SHR-A2009
Time frame: approximately 6 months
AUC0-∞ of SHR-A2009
Time frame: approximately 6 months
Immunogenicity of SHR-A2009
Time frame: approximately 9 months
Overall response rate (ORR)
Time frame: approximately within 36 months
Duration of response (DoR)
Time frame: approximately within 36 months
Disease control rate (DCR)
Time frame: approximately within 36 months
Progression-free survival (PFS)
Time frame: approximately within 36 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Advanced Solid Tumors
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
RecruitingPhase 1/2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
16 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing SHR-A2009 in people with Advanced Solid Tumors, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd. at 16 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 16 sites in China, South Korea, Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maximum tolerated dose (MTD) or maximum administered dose (MAD). (time frame: From Day 1 to Day 21). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.